Is Tirzepatide a GLP-1 Medicine — and Why Does It Matter?

Does tirzepatide work through the GLP-1 pathway?

Yes, but that framing undersells it. GLP-1 receptor agonism is one of two mechanisms tirzepatide uses. When you eat, your gut releases GLP-1, which tells the pancreas to secrete insulin, slows the rate at which food leaves the stomach, and sends a satiety signal to the brain. Medicines that mimic this hormone (semaglutide being the most widely known) produce real, clinically meaningful weight loss by leaning on those effects.

Tirzepatide does all of that. The difference is that it also binds to GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone released after eating. Its exact role in weight regulation is still being studied, but the current evidence suggests it amplifies insulin secretion in a glucose-dependent way and may influence how the body handles fat tissue. Activating both receptors together appears to produce a stronger combined effect than activating either alone. The NHS medicines page on tirzepatide describes it as a dual GIP and GLP-1 receptor agonist, worth bookmarking if you want a quick, trustworthy one-stop reference.

So: is tirzepatide a GLP-1 medicine? Technically yes, in that GLP-1 receptor activation is part of what it does. But it is more accurately described as a dual-agonist, which is why you will see it classified separately in clinical literature and regulatory documents.

How does the dual mechanism change the results picture?

The practical difference showed up clearly in the SURMOUNT-1 trial, published in the New England Journal of Medicine, where tirzepatide produced an average body-weight reduction of around 20–21% at the highest dose over 72 weeks. That figure placed it above what GLP-1-only trials had reported at equivalent timepoints.

The head-to-head comparison came with SURMOUNT-5, also published in the New England Journal of Medicine in 2025. In 751 adults with obesity and without diabetes, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. That is the most direct evidence we have that the dual mechanism translates into a measurable difference in outcomes, not just a laboratory distinction. How GLP-1 and tirzepatide relate to each other is worth reading if you want to go deeper on where the two approaches overlap and diverge.

None of this means one medicine is universally better for every person. Semaglutide has a well-established record and suits many patients. Which is appropriate for you is a clinical decision, not a marketing one.

Is Mounjaro the same as a GLP-1 injection?

Mounjaro is the UK brand name for tirzepatide. It is a once-weekly injection delivered via a pre-filled KwikPen, available in six strengths from 2.5mg to 15mg. Treatment starts at 2.5mg, which exists to allow the body to adjust rather than as a therapeutic dose, and is titrated upward by a prescriber in steps over time.

You will sometimes hear people group Mounjaro with GLP-1 injections as a shorthand, and it is not wrong, it shares the GLP-1 component. But it sits in its own pharmacological class. Mounjaro's full treatment profile covers the specifics of how the pen works, what the titration schedule looks like, and what to expect from each stage. For those wondering about the broader category, whether Mounjaro counts as a GLP-1 is addressed in more detail there, and if you are curious how GLP-1 compares to Mounjaro more broadly, that question is unpacked there too.

The licence in the UK covers weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Mounjaro carries a Black Triangle (▼) symbol, meaning it is subject to additional monitoring by the MHRA while post-market safety data continues to accumulate.

What does 'GLP-1 or tirzepatide' mean when you are choosing a treatment?

If you are researching weight-loss injections, you have probably seen both terms used in the same breath. The practical question is whether GLP-1-only medicines or a dual-agonist like tirzepatide is the right starting point for you, and that is exactly what a clinical assessment is for. Eligibility, medical history, current medications and personal circumstances all feed into that decision. If you want to understand how GLP receptors and tirzepatide interact in practice, that page sets out the mechanism in plain terms. It is also worth understanding how GLP-2 fits into the tirzepatide picture, since the incretin system involves more than one pathway and the distinctions matter when comparing treatments.

It is worth spending sixty seconds on the GPhC pharmacy register before placing any order with an online provider: every legitimate dispensing pharmacy has a registered premises number listed there, which you can look up in seconds. That small habit filters out a lot of risk.

For a broader view of how tirzepatide fits into the UK weight-loss treatment landscape, our weight-loss treatment overview covers the options currently available through prescription. If you are considering whether to start a conversation with a prescriber, starting a free consultation is the natural next step, a GPhC-registered Independent Prescriber reviews your information the same day, not an automated system.